How to Select a Microbiology Contract Testing Laboratory? Tony Cundell, Ph. D. Microbiological Consulting, LLC Scarsdale, New York
|
|
- Irene Jennings
- 5 years ago
- Views:
Transcription
1 How to Select a Microbiology Contract Testing Laboratory? Tony Cundell, Ph. D. Microbiological Consulting, LLC Scarsdale, New York June 13, 2017 IVT Microbiology Week 1
2 Presentation Overview Rationale for outsourcing your microbiological testing Selection parameters Pre audit questionnaire Audit objectives Difference between a business contract and a quality agreement Important issues in building the relationship Method validation/suitability testing 483 observations Failure investigations Response to FDA Quality Metrics program June 13, 2017 IVT Microbiology Week 2
3 Microbiological Testing June 13, 2017 IVT Microbiology Week 3
4 Benchmarking Questions Who in the audience works for companies that have outsourced routine microbiological testing? Is it a trend that is growing in the pharmaceutical industry or not? What was your experience with the process? June 13, 2017 IVT Microbiology Week 4
5 Rationale for Outsourcing Today, while the need to innovate remains more strategic and imperative than ever, it is no longer the case that routine laboratory testing support need be. Outsourcing laboratory functions to a dedicated, independent, third party service provider can not only deliver savings and strategic commercial benefit to a manufacturing company but also increase corporate market agility for responsiveness in today s fast moving and global market place. Eric Creveling, Director, Whitehouse Laboratories, Princeton, New Jersey June 13, 2017 IVT Microbiology Week 5
6 Rationale for Outsourcing Outsourcing has been widely employed by the pharmaceutical industry to improve efficiency and reduce costs. The most commonly outsourced CMC activity is analytical testing. This market is growing at a fast pace: the global healthcare analytical testing market is projected to expand from $2.42 billion in 2016 to $4.13 billion by 2021 at a compound annual growth rate of 11.3%. Major areas of testing stability testing, raw material testing, method validation, microbial testing, environmental monitoring, physical characterization, batch release testing, and bioanalytical testing. June 13, 2017 IVT Microbiology Week 6
7 Rationale for Outsourcing Microbiology managers, supervisors and analysts should ask themselves, what value do you bring to your company, are your activities considered part of the core competencies of your company, and can your services be better obtained at a lower cost by outsourcing these activities? The reality is that the ability to do routine microbiological testing, even when done well and in a timely manner, may be insufficient a contribution to your company to have strategic value. June 13, 2017 IVT Microbiology Week 7
8 Benchmarking Questions What are the most value added activities that microbiologists can bring to a pharmaceutical company? Method development and specification setting Microbial contamination risk assessment CMC Section drafting Validation of sterilization and depyrogenation processes Microbial contamination investigations Drafting replies to regulatory findings Product release and stability testing June 13, 2017 IVT Microbiology Week 8
9 Outsourcing Models There are three different outsourcing models: Fee for Service Analytical work performed at the contract testing laboratory. On site Leased Microbiologists Contract or temporary staff nested in your laboratories supervised by your management. Technical In sourcing Services Dedicated facilities, equipment, and personnel within your facility with project management, supervision and analysts supplied by the contract testing laboratory. June 13, 2017 IVT Microbiology Week 9
10 Downside to Outsourcing Microbial Testing Stripping out expertise in microbiology from your organization Loss of a department that recruits entry level staff to your organization Less emphasize on microbial contamination risk assessment, exposing your company to serious business risks Loss of hands on experience in testing products Additional hand offs during release and stability testing, data review and failure investigations Exposure to greater compliance risks Danger of loss of intellectual property June 13, 2017 IVT Microbiology Week 10
11 GMP Regulations Why must we conduct release testing: Laboratory testing, which is required by the CGMP regulations and , is necessary to confirm that components, containers and closures, in process materials, and finished products conform to specifications, including stability specifications. General CGMP regulations covering laboratory operations can be found in 21 CFR 211, subparts I (Laboratory Controls) and J (Records and Reports). June 13, 2017 IVT Microbiology Week 11
12 GMP Regulations These regulations provide for the establishment of scientifically sound and appropriate specifications, standards, and test procedures that are designed to ensure that components, containers and closures, in process materials, and finished drug products conform to the established standards. Section (f) of the CGMP regulations specifies that finished drug products that fail to meet established standards, specifications, or other relevant quality control criteria will be rejected. June 13, 2017 IVT Microbiology Week 12
13 GMP Regulations How do these GMP regulations effect contract testing? The responsibility of a contract testing laboratory in meeting these requirements is equivalent to that of a manufacturing firm. From 2006 FDA Guidance for Industry Investigating Out of Specification (OOS) Test Results for Pharmaceutical Production June 13, 2017 IVT Microbiology Week 13
14 Presentation Overview Rationale for outsourcing your microbiological testing Selection parameters Pre audit questionnaire Audit objectives Difference between a business contract and a quality agreement Important issues in building the relationship Method validation/suitability testing Failure investigations 483 observations Response to FDA Quality Metrics program June 13, 2017 IVT Microbiology Week 14
15 Lab Selection Parameters Important selection parameters for a contract testing lab include: Technical reputation Compliance level as demonstrated in external audits Access to routine and specialized testing procedures Location Scheduling Opportunity to develop a partnership Cost June 13, 2017 IVT Microbiology Week 15
16 Cost Inventory Remember that contract testing costs include the following: Negotiating the contract Managing the relationship Scheduling the testing Sample shipment Method validation Conducting the microbial tests Sample disposal Reviewing the results Conducting failure investigations Monitoring contract lab inspections June 13, 2017 IVT Microbiology Week 16
17 Testing Strategies Two broadly difference strategies are: Moving routine microbiological testing to a contract testing laboratory Outsourcing highly specialized testing that may be conducted infrequently to a contract testing laboratory June 13, 2017 IVT Microbiology Week 17
18 Benchmarking Questions Who is the audience has participated in the selection of a contract testing laboratory? Did you participate in the audit of candidate contract testing laboratories or not? Are you a contact person with the contract testing laboratory? What was your experience with these activities? June 13, 2017 IVT Microbiology Week 18
19 Presentation Overview Rationale for outsourcing your microbiological testing Selection parameters Pre audit questionnaire Audit objectives Difference between a business contract and a quality agreement Important issues in building the relationship Method validation/suitability testing Failure investigations 483 observations Response to FDA Quality Metrics program June 13, 2017 IVT Microbiology Week 19
20 Pre audit questionnaire How can you build sufficient information as to the suitability of a contract testing laboratory? Review the lab s website Visit their exhibition booth at a regional or national technical conference Request a customer list Benchmark with colleagues at other companies Conduct a telephone conference Submit a pre audit questionnaire June 13, 2017 IVT Microbiology Week 20
21 Pre audit questionnaire Although requesting that the contract laboratory fill out a questionnaire is no substitute for a site GMP audit, they can be useful in both the lab selection process, and as a preparation for a site audit. Remember it is human nature to inflate our capabilities and even deceive to obtain the business. Be careful. Require that the questionnaire by signed and dated by a responsible representative of the contract lab to ensure accountability. June 13, 2017 IVT Microbiology Week 21
22 Pre audit Questionnaire Request the following information and supporting documents: Summary of the company registration, ownership and financial viability Organizational chart including managing director, laboratory director, microbiology supervisor, analysts, and quality head Laboratory facility floor plan with critical equipment locations Laboratory certifications/accreditations suitable for the North American region, e.g., ISO or equivalent, compliance with 21 CFR Laboratory Records, ISO 9001 quality systems certification, and FDA registration number. June 13, 2017 IVT Microbiology Week 22
23 Pre audit Questionnaire List of microbial tests that can be performed Analytical instrument list for compendial testing of excipients, active pharmaceutical ingredients and drug products Process flow chart (identifying critical stages and points of sample receipt, testing and reporting) Standard operating procedures (SOP) manual table of contents. Out of specification reporting and investigation procedures June 13, 2017 IVT Microbiology Week 23
24 Pre audit Questionnaire Change control Staff educational requirements and training procedures Sample receipt/chain of custody/retention procedures Sample submission form/chain of custody Standard turnaround times along with associated rush charges. Fee schedule for data packets and investigations June 13, 2017 IVT Microbiology Week 24
25 Pre audit Questionnaire Critical facility and equipment service agreements Price list including: test, test method reference, model method suitability reports and instrumentation used Volume of microbial tests conducted annually Copies of recent regulatory inspections reports, e.g., 483 observation forms and their replies. Quality Metrics June 13, 2017 IVT Microbiology Week 25
26 Audit Objectives What does the FDA emphasize when inspecting contractors? The inspectors from FDA thoroughly audited WuXi s quality system during the 5 day inspection of their Bioanalytical Services Unit in Shanghai, China, focusing on scientific data integrity, operation infrastructure, equipment, sample storage, archival system, quality control, and quality assurance. The inspection covered bioequivalence studies for preapproval including method validation and sample analysis and other clinical bioanalytical studies from as a general regulatory compliance inspection. June 13, 2017 IVT Microbiology Week 26
27 Audit Objectives Senior Vice President and COO of WuXi Lab Testing Division, Dr. Jason Liu, commented, FDA has the most stringent requirement on quality and data integrity among international regulatory agencies. We are proud with the result of this audit. We will continue to maintain the highest quality standards, and provide the best in class R&D services for our customers worldwide. June 13, 2017 IVT Microbiology Week 27
28 Audit Objectives Your key objectives when auditing a contract testing lab are: Does the lab have the facilities, equipment and trained lab analysts to conduct the testing? Will the testing be of high quality and completed in a timely manner? Is their testing well documented? Are their failure investigations robust? Should you anticipate any compliance issues? Will you develop a partnership with the testing lab with good communications June 13, 2017 IVT Microbiology Week 28
29 Presentation Overview Rationale for outsourcing your microbiological testing Selection parameters Pre audit questionnaire Audit objectives Difference between a business contract and a quality agreement Important issues in building the relationship Method validation/suitability testing Failure investigations 483 observations Response to FDA Quality Metrics program June 13, 2017 IVT Microbiology Week 29
30 Difference between Business and Quality Agreements Business agreements gives general business terms, defines financial arrangements, designates services to be provided, gives notice of price increases, establishes confidentiality rules, and as contract usually has legal approval. Quality agreements defines working relations in terms of GMP compliance and should be attached to or cited in the business agreement. June 13, 2017 IVT Microbiology Week 30
31 Quality Agreements In November 2016, the FDA issued their Guidance for Industry Contract Manufacturing Arrangements for Drugs: Quality Agreements. In the guidance document it was emphasized that a contract testing laboratory may be viewed as an extension of your Quality Unit. See 21 CFR Responsibilities of quality control unit June 13, 2017 IVT Microbiology Week 31
32 Quality Agreements The FDA recommends that the quality agreements should contain the following sections at a minimum: Purpose and scope of the contract agreement Terms of the agreement, including its effective dates Terms for dispute resolution Responsibility of each respective party, including an overview of the subparts of the CGMP regulations Change control and revision practices See more at: online/news/news article view/ article/3519/#sthash.fllvzh1g.dpuf June 13, 2017 IVT Microbiology Week 32
33 Quality Agreements What is the scope of the FDA Guidance for Industry? The FDA clarified that the guidance applies to any organization involved in processing, packing, holding, labeling operations, testing, and operations of the Quality Unit when it comes to making active pharmaceutical ingredients (APIs or drug substances, or their intermediaries), finished drug products, combination products, and biological drug products intended for commercial sale and/or distribution. See more at: view_features/fdas quality agreement guidance vs emascgmpregulations#sthash.abwrysn8.dpuf June 13, 2017 IVT Microbiology Week 33
34 Quality Agreements The impetus for Quality Agreements comes from several cgmp guidelines published by the International Conference on Harmonization (ICH), specifically Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (2000), Q9: Quality Risk Management (2005), and Q10: Pharmaceutical Quality System (2008). The EU s revised cgmp Chapter 7: Outsourced Activities specifically cites the ICH Q10 guideline as a driving reason for the revision of Chapter 7 and the controls therein. June 13, 2017 IVT Microbiology Week 34
35 Quality Agreements What should be included in a Quality Agreement? Names and Addresses of the Two Parties Responsibility Matrix Contact List Microbial Testing List Test Specifications Test Reporting Method Validation/Qualification Requirements Sample Receipt and Retention June 13, 2017 IVT Microbiology Week 35
36 Quality Agreements What should be included in a Quality Agreement? Record Retention Derivations/Out of specification Investigations Dispute Resolution Audits/Inspection Rights Change Control Notification of Adverse FDA Inspection Findings Quality Metrics Reporting Requirements June 13, 2017 IVT Microbiology Week 36
37 Presentation Overview Rationale for outsourcing your microbiological testing Selection parameters Pre audit questionnaire Audit objectives Difference between a business contract and a quality agreement Important issues in building the relationship Method validation/suitability testing Failure investigations 483 observations Response to FDA Quality Metrics program June 13, 2017 IVT Microbiology Week 37
38 Building the Relationship It is useful for your microbiology subject matter expert to be included in the audit team or visit the contract testing lab to build a relationship. The contact persons and their back ups should be clearly established in both organization. The mode of routine communication, i.e., fax, , telephone or website downloads should be established. June 13, 2017 IVT Microbiology Week 38
39 Presentation Overview Rationale for outsourcing your microbiological testing Selection parameters Pre audit questionnaire Audit objectives Difference between a business contract and a quality agreement Important issues in building the relationship Method validation/suitability testing Failure investigations Response to FDA Quality Metrics program June 13, 2017 IVT Microbiology Week 39
40 Method Validation/Suitability Testing For the results to be valid, the USP test methods must be followed and the method suitability testing requirements met. Without meeting these requirements, you cannot claim that the product meets the USP microbial requirements and the FDA approved test. Suitability testing is usually conducted with lots of the drug product and multiple challenge microorganisms and is time consuming and expensive. June 13, 2017 IVT Microbiology Week 40
41 Most Common Microbial Tests USP <51> Antimicrobial effectiveness testing USP <61> Microbiological examination of non sterile products: Microbial enumeration tests USP <62> Microbiological examination of non sterile products: Tests for specified microorganisms USP <71> Sterility tests USP <85> Bacterial endotoxins test APHA/AWWA water testing Environmental monitoring Bioburden testing Microbial identification June 13, 2017 IVT Microbiology Week 41
42 Specialized Microbial Tests Container closure Integrity Tests Microbial Assays of Vitamins and Antibiotics Mycoplasma Tests Strain Typing Disinfectant Effectiveness Studies June 13, 2017 IVT Microbiology Week 42
43 Benchmarking Questions What microbiological test does your lab outsource? Microbial identification? Strain typing? Mycoplasma screening? Container closure integrity testing. Sterile filtration validations? Other tests? June 13, 2017 IVT Microbiology Week 43
44 Presentation Overview Rationale for outsourcing your microbiological testing Selection parameters Pre audit questionnaire Audit objectives Difference between a business contract and a quality agreement Important issues in building the relationship Method validation/suitability testing Failure investigations 483 observations Response to FDA Quality Metrics program June 13, 2017 IVT Microbiology Week 44
45 Failure Investigations Out of specification results will generate a laboratory investigation to determine if the sample was not compromised, the test was conducted correctly and the results are valid. This investigation will be conducted by the contract testing laboratory following a procedure approved by the client and will be fully documented. The client manufacturer would proceed with the manufacturing investigation, if the test was found to be valid. June 13, 2017 IVT Microbiology Week 45
46 Benchmarking Questions Is there adequate guidance available on microbiology failure investigations? What microbial test results are involved most frequently in laboratory investigations? How frequently does the investigation result in the invalidation of a test? Are drug products released after the invalidation of a test? June 13, 2017 IVT Microbiology Week 46
47 Simple Fishbone Diagram June 13, 2017 IVT Microbiology Week 47
48 June 13, 2017 IVT Microbiology Week 48
49 Failure Investigation The FDA Guidance for Industry, Investigating Out of Specification Test Results for Pharmaceutical Production states that contract testing labs should report their data, findings, and supporting documentation to the QC unit of the drug manufacturer, who should then, as necessary, initiate an OOS investigation. The guidance document describes the responsibility of the analyst and lab supervisor in conducting the lab investigation and emphasizes that lab error should be relatively rare, but when clear evidence of lab error exists, the results should be invalidated. June 13, 2017 IVT Microbiology Week 49
50 Laboratory Investigations In practice, the contract testing lab should know the test specification for the product being tested and immediately start a lab investigation using a procedure agreed upon by the contacting lab and your customer. OOS investigations and their outcomes should logged and trended. Importantly, the contract testing lab must trend invalidated OOS results as a measure of their analytical performance. The root cause of the invalidated result should be established and corrective action taken, i.e., CAPA. June 13, 2017 IVT Microbiology Week 50
51 Laboratory Investigations Whenever a laboratory error is identified, the source of the error would be determined and corrective action taken. Conversely, when no evidence of laboratory error is clear, the customer should conduct an investigation of their manufacturing operation, which is outside the scope of the contract testing laboratory. June 13, 2017 IVT Microbiology Week 51
52 Presentation Overview Rationale for outsourcing your microbiological testing Selection parameters Pre audit questionnaire Audit objectives Difference between a business contract and a quality agreement Important issues in building the relationship Method validation/suitability testing Failure investigations 483 observations Response to FDA Quality Metrics program June 13, 2017 IVT Microbiology Week 52
53 External Audits Contract testing laboratories are subject to external audits including: Customer audits for qualification or in response to test failures Audits from certification authorities FDA registration audits, recall follow ups and riskbased GMP inspections June 13, 2017 IVT Microbiology Week 53
54 FDA Warning Letter January 2012 warning letter to Biochem Laboratories Inc. Lyndhurst, NJ During our May 18, 2011 through June 15, 2011 inspection of your pharmaceutical contract testing laboratory, Biochem Laboratories Inc., located at 56 Park Avenue, Lyndhurst, New Jersey, investigators from the FDA identified significant violations of the CGMP regulations for Finished Pharmaceuticals, 21 CFR, Parts 210 and 211. These violations cause your clients' drug products to be adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 351(a)(2)(B)] in that the methods used in, or the facilities or controls used for, their manufacture, processing, packing, or holding do not conform to, or are not operated or administered in conformity with, CGMP. June 13, 2017 IVT Microbiology Week 54
55 FDA Warning Letter January 2017 letter to Porton Biopharma, Limited, Porton Downs, UK: Firms acting as contract manufacturers must comply with cgmp. FDA is aware that many pharmaceutical product manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer. You and your customer, Jazz Pharmaceuticals, have a quality agreement regarding the manufacture of Erwinaze. Regardless of this agreement, you are both responsible for the quality of drugs released and ultimately administered to patients. June 13, 2017 IVT Microbiology Week 55
56 MHRA Inspection Trends The 2015 UK Medicines and Healthcare Products Regulatory Agency GMP Inspections trends: There was no proceduralized assessment of the suitability of the Contract Acceptor There had been no documented assessment of the suitability of Contract Acceptor Technical Agreements and audits were not in place for a number of suppliers There was no inventory of Technical Agreements for outsourced activities and no review period Assessment of the competence of outsourced service providers was not always completed June 13, 2017 IVT Microbiology Week 56
57 Method Suitability Testing An FDA Warning Letter dated February 17, 2014 to a contract testing Biochem Laboratories, Inc, the Director of the New Jersey District wrote the following: In your response, you state that you have informed your clients on the importance of validating the methods, but they have chosen not to validate the methods. In addition, you state that you will inform them again in writing. Your response, however, is inadequate because you do not provide your firm s planned corrective actions for this cgmp violation. You are responsible for ensuring that the test methods used by your firm are validated. June 13, 2017 IVT Microbiology Week 57
58 Method Suitability Testing Your firm has failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of test methods [21 CFR (e)]. Your firm failed to validate the specificity of the test procedures used to analyze finished product stability samples to ensure that the methods are stabilityindicating. For example, your firm determined the content of salicylic acid in (b)(4) stability samples by titration. Your firm has not demonstrated the specificity of the method for degradation products. June 13, 2017 IVT Microbiology Week 58
59 Presentation Overview Rationale for outsourcing your microbiological testing Selection parameters Pre audit questionnaire Audit objectives Difference between a business contract and a quality agreement Important issues in building the relationship Method validation/suitability testing Failure investigations 483 observations Response to FDA Quality Metrics program June 13, 2017 IVT Microbiology Week 59
60 Quality Metrics On July 28, 2015, FDA published Draft Guidance for Industry: Request for Quality Metrics in the Federal Register with a 60 day comment period. The intention of this long anticipated document is to establish a risk based frequency for the regulatory inspection program for pharmaceutical companies through review of quality metrics data on lot rejection rates, frequency of invalidated out ofspecification (OOS) results, product complaints, and on time rates for annual product and quality review reporting. June 13, 2017 IVT Microbiology Week 60
61 Benchmarking Questions Are you aware of the FDA program on Quality Metrics? Does your lab maintain quality metrics? Have FDA investigators requested information on the rate of invalidation of microbial tests? June 13, 2017 IVT Microbiology Week 61
62 Quality Metrics In 2016, the FDA released a draft Guidance for Industry, Request for Quality Metrics, which described the FDA s intent to require 10 types of quality data from the industry for both drug owners and their contractors, so that 4major quality metrics Lot Acceptance Rate, Product Quality Complaint Rate, Invalidated Out of Specification Rate and Annual Product Review on Time Rate can be calculated. The primary FDA use of the quality metrics is to develop risk based drug inspection schedules and address potential drug shortages See June 13, 2017 IVT Microbiology Week 62
63 FDA Intentions Quality metrics reporting would justify reduced general, pre approval, and post approval manufacturing change inspections and improve overall quality in the pharmaceutical industry. Taking up the theme introduced by Jill Wechsler in her July 29, 2015 Regulatory Beat column, the carrots for the pharmaceutical industry are the promise of a reduced frequency of regulatory inspections, whereas the stick if quality metrics are not reported is the possibility of having products designated as adulterate in terms of the Federal Food, Drug, and Cosmetic Act (FD&C Act). June 13, 2017 IVT Microbiology Week 63
64 Affect on Contract Testing Labs Are contract testing laboratories conducting release and stability testing for drug manufacturers required to maintain and report quality metrics? The short answer is, probably no. Of the seven major quality metrics FDA plans to monitor number of lots attempted, number of lots rejected, number of tests conducted, number of OOS results, number of invalidated OOS results, number of lots released, and number of product complaints for each drug product only the quality metrics related to OOS results directly impact contract testing labs. June 13, 2017 IVT Microbiology Week 64
65 Lab Investigations The FDA Guidance for Industry, Investigating Out of Specification Test Results for Pharmaceutical Production states that contract testing labs should report their data, findings, and supporting documentation to the QC unit of the drug manufacturer, who should then, as necessary, initiate an OOS investigation. The guidance document describes the responsibility of the analyst and lab supervisor in conducting the lab investigation and emphasizes that lab error should be relatively rare, but when clear evidence of lab error exists, the results should be invalidated June 13, 2017 IVT Microbiology Week 65
66 Quality Metrics In practice, a contract testing lab should know the test specification for the product being tested and immediately start a lab investigation using a procedure agreed upon by the contacting lab and your customer. OOS investigations and their outcomes should logged and trended. Importantly, the contract testing lab must trend invalidated OOS results as a measure of their analytical performance. The root cause of the invalidated result should be established and corrective action taken. June 13, 2017 IVT Microbiology Week 66
67 Quality Metrics How will these regulatory changes impact contract testing laboratories? With OOS results being a key quality metric, more attention must be given to this crucial area. As an observer of the state of contract testing, I see many challenges resulting from these upcoming regulatory changes. June 13, 2017 IVT Microbiology Week 67
68 Quality Metrics Samples may be submitted by pharmaceutical companies to contract testing laboratories via purchase orders with one or more of the following issues: No identification as to dosage form and product name; Test procedures requested that are not fully described Sample size may not comply with compendial test requirements Testing laboratories may not be fully aware of product specifications Test methods may not be adequately qualified. June 13, 2017 IVT Microbiology Week 68
69 Quality Metrics These potential issues all make it difficult for the contract laboratory to test, evaluate, and identify an OOS result. Although a manufacturer may reject a lot based on the reported results from the contract laboratory, this does not negate the need to perform an OOS investigation. In a few isolated cases, misguided manufacturers may resubmit additional samples from the same batch for testing without the knowledge of the contract laboratory in an attempt to test the product into compliance with the specification. June 13, 2017 IVT Microbiology Week 69
70 Quality Metrics Because many manufacturers are increasingly outsourcing release and stability testing as a costsavings strategy, they may be tempted to skimp on ordering OOS investigations. The requirements for annually reporting lots attempted, OOS results, OOS results invalidated, and lots rejected will open a manufacturer up to additional regulatory scrutiny. June 13, 2017 IVT Microbiology Week 70
71 Conclusions As microbiologists we should be involved in any decisions to outsource microbiological testing Get involved to take care of the interests of your staff and the reputation of your company. Thank for your attention. Are there any additional questions or comments? June 13, 2017 IVT Microbiology Week 71
Subpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationPorton Biopharma Limited 1/17/17
Porton Biopharma Limited 1/17/17 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320 17 19 Return Receipt Requested January 19, 2017 Dr. Roger J. Hinton Managing Director Porton
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations
More informationCOMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS
COMPLIANCE BY DESIGN FOR PHARMACEUTICAL QUALITY CONTROL LABORATORIES INSIGHT FROM FDA WARNING LETTERS Primer CONTENTS INTRODUCTION...3 QUALITY AND COMPLIANCE IN QUALITY CONTROL LABORATORIES...5 Compliance
More informationIDT Australia Ltd. 5/23/18
IDT Australia Ltd. 5/23/18 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320-18-55 Return Receipt Requested May 23, 2018 Dr. Graeme R. Kaufman CEO, Acting, and Chairman of the
More informationLABORATORY COMPLIANCE
1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationMahendra Chemicals 7/13/15
Mahendra Chemicals 7/13/15 Department of Health and Human Services Public Health Service Food and Drug Administration Silver Spring, MD 20993 CERTIFIED MAIL RETURN RECEIPT REQUESTED July 13, 2015 Mr. Rajnibhai
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 5 Inspections, Compliance, Enforcement, and Criminal Investigations Hill Dermaceuticals, Inc. Department of Health and Human Services Public Health Service Food and Drug Administration Food and
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Nostrum Laboratories Inc 4/27/09 Department of Health and Human Services Public Health Service Food and Drug Administration Kansas City
More informationOOS: Back to Basics. Compliant, Effective, Efficient PATH
OOS: Back to Basics Even with the number of trainings, seminars, online webinars and consultant guided investigations, companies are still seeing FDA 483 observations around how they are handling and investigating
More informationInspection Trends. American Society for Quality Richmond, VA Section March 8, 2016
Inspection Trends American Society for Quality Richmond, VA Section March 8, 2016 Brooke K. Higgins, Senior Policy Advisor CDER / Office of Compliance Office of Manufacturing Quality Division of Drug Quality
More informationCBER Expectations Regarding Contract Manufacturing
CBER Expectations Regarding Contract Manufacturing LCDR Qiao Bobo, Ph.D. FDA/CBER/OCBQ/DMPQ CASSS CMC Strategy Forum Summer 2014 Outline 2 Types of Cooperative Manufacturing Arrangements CBER Expectations
More informationGMP Requirements. Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP)
GMP Requirements Gabriel Kaddu, Senior GMP Specialist Promoting the Quality of Medicines Program (PQM) U.S. Pharmacopeial Convention (USP) 2016. ALL RIGHTS RESERVED. Outline GMP Procedures and standards
More informationTop Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp
Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp 2016 Regulatory Compliance Associates Inc. Top Observation for 5 years Year Drugs #1 citation Device #1 citation
More informationCurriculum Vitae. SENIOR VICE PRESIDENT JAMES P. KULLA Mobile Phone:
Curriculum Vitae SENIOR VICE PRESIDENT JAMES P. KULLA Mobile Phone: 240.413.3350 Summary of Qualifications Jim has been active in the medical products industry since 1967. Jim founded a company in 1980
More informationPreparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014
Preparing Your Aseptic Processing Facility for an FDA Inspection Valerie Welter, Director Quality Bayer HealthCare March 10, 2014 Agenda Regulatory Requirements Establishing your Approach Aseptic Controls
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Laboratoire Atlas Inc. 6/25/09 hhsbluebird Department of Health and Human Services Public Health Service Food and Drug Administration
More informationICH Q8/Q8(R)
Pharmaceutical Quality for the 21 st Century Temple University May 06, 2008 Joseph Famulare, Deputy Director FDA CDER Office of Compliance CDER Office of Compliance and the Critical Path Initiative Since
More information21CFR Ventilation, air filtration, air heating and cooling. 21CFR211 Details, Details. 21CFR Equipment Cleaning and Maintenance
21CFR211 Details, Details Kirsten L. Vadheim, Ph.D., RAC 7710 196th Avenue N.E. Redmond WA 98053 Tel: 651.260.6560 Fax: 425.868.4302 klvadheim@hotmail.com 21CFR211.46 Ventilation, air filtration, air heating
More informationLaboratory OOS Investigations The Missing Link
Laboratory OOS Investigations The Missing Link India Pharmaceutical Alliance Carmelo Rosa, Psy.D Director Division of Drug Quality I November 6-17, 2017 Indian Pharmaceutical Alliance DISCLAIMER: The views
More informationUSP Chapter 823 USP 32 (old) vs. USP 35 (new)
USP Chapter 823 USP 32 (old) vs. USP 35 (new) Sally W. Schwarz, MS, BCNP Research Associate Professor of Radiology Washington University School of Medicine St. Louis, MO Why USP Chapter ? FDA has
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Lloyd Inc. of Iowa
More informationQUALITY AGREEMENT. The following Agreement has been concluded between
QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter
More informationLifecycle Product Quality Risk Management
Lifecycle Product Quality Risk Management Richard L. Friedman, M.S. Associate Director Office of Manufacturing and Product Quality Office of Compliance IFPAC Annual Meeting (Arlington, VA) January, 21-24,
More informationCERTIFIED MAIL RETURN RECEIPT REQUESTED
Department of Health and Human Services Public Health Service Food and Drug Administration Warning Letter WL: 320-14-11 CERTIFIED MAIL RETURN RECEIPT REQUESTED June 16, 2014 Jeremy B. Desai, PhD President
More informationBen Venue Laboratories, Inc. 16-Nov-07
Ben Venue Laboratories, Inc. 16-Nov-07 Department of Health and Human Services Public Health Service Food and Drug Administration Cincinnati District Office Central Region 6751 Steger Drive Cincinnati,
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationPharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit
Pharmaceutical Good Manufacturing Practice Page 1 of 6 Why Attend A robust quality system that meets the requirements of pharmaceutical regulators is an essential element of every good pharmaceutical manufacturing
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationJeff Yuen and Associates, Inc. PO Box 6026 Orange, CA Zenaida Power Regulatory Expertise:
Regulatory Expertise: Pharmaceuticals: Sterile-Liquids, Non-Sterile Liquids, Solid Oral Dosage Form, Parenterals, Antibiotics, APIs/Bulk Chemicals, Creams & Ointments Medical Devices: Implantable / Active
More informationLessons from Pharmaceutical Laboratory related FDA Warning Letters
Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationGood Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED
Good Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED Presented by Raymond A. Bonner Nathan C. Sheers SIDLEY AUSTIN BROWN & WOOD, LLP Washington, D.C. (202) 736-8000 To The Fourth Annual Pharmaceutical
More informationInterpharm Praha A.S. 10/18/16
Interpharm Praha A.S. 10/18/16 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Return Receipt Requested
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationSan Jose, California, USA
Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System
More informationWhile the recognition
Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change
More informationInspections, Compliance, Enforcement, and Criminal Investigations
1 of 7 6/10/2009 12:50 PM Inspections, Compliance, Enforcement, and Criminal Investigations Department of Health and Human Services Public Health Service Food and Drug Administration Central Region Waterview
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationSupply Chain Supplier Quality Management. Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District
Supply Chain Supplier Quality Management Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District 1 Overview Product Life Cycle Maintaining Quality in Supply Chain FDA and ICH Guidances
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationSeptember 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
September 2, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Draft Guidance: Current Good Manufacturing Practice Interim
More informationMetrics in Microbiology Monitoring Practices
Metrics in Microbiology Monitoring Practices Crystal Booth, M.M. Masters of Microbiology from North Carolina State University Former Associate Director of Microbiology at Novartis Metrics in Microbiology
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Dabur Oncology PLC hhsbluebird Department of Health and Human Services Warning Letter Public Health Service Food and Drug
More informationCompliance Trends Paula Katz
Compliance Trends Paula Katz Director, Manufacturing Quality Guidance and Policy Staff Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research India Pharmaceutical
More informationTextvergleich. Verglichene Dokumente MEDIA3917.pdf. ICH_Q10_Step4.pdf
Textvergleich Verglichene Dokumente MEDIA3917.pdf ICH_Q10_Step4.pdf Übersicht 2270 Wort/Wörter hinzugefügt 1338 Wort/Wörter gelöscht 3558 Wort/Wörter übereinstimmend 157 Block/Blöcke übereinstimmend Blättern
More informationVital Laboratories Pvt Ltd Plant II 10/10/17
Vital Laboratories Pvt Ltd Plant II 10/10/17 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320-18-01 October 10, 2017 Mr. Rajiv Bajaj Director Vital Laboratories Private Limited
More informationPage 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations
More informationGMP On Site Series. GMP Essentials
GMP On Site Series GMP Essentials GMP Basics Objectives 1. State the critical definitions of the pharmaceutical industry. 2. Describe the law as it applies to various critical functions. 3. State the history
More informationSupplier Oversight PQRI. September Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan
Supplier Oversight September 2014 PQRI Steven Lynn, MS, CMQ/OE Vice President Global Quality Compliance Mylan Agenda Mylan Background Setting the Stage with a Scenario Current State Thinking Supplier Qualification
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationWARNING LETTER CMS #
U.S. Food and Drug Administration Division of Pharmaceutical Quality Operations I 10 Waterview Blvd 3rd FL, Parsippany NJ 07054 Telephone: (973) 331-4900 Fax: (973) 331-4969 www.fda.gov Via UPS Next Day
More informationá1225ñ VALIDATION OF COMPENDIAL PROCEDURES
1640 á1224ñ Transfer of Analytical Procedures / General Information USP 39 THE ANALYTICAL PROCEDURE The procedure should be written with sufficient detail and explicit instructions, so that a trained analyst
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 HomeInspections, Compliance, Enforcement, and Criminal InvestigationsEnforcement ActionsWarning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Capco Custom Packaging
More informationNavigating an FDA GMP and Validation Inspection- Best Practices and Pitfalls
Navigating an FDA GMP and Validation Inspection- Best Practices and Pitfalls Sonali P. Gunawardhana FDA Practice Group Wiley Rein LLP 1776 K Street NW Washington, DC (202) 719-7454 sgunawardhana@wileyrein.com
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home > Inspections, Compliance, Enforcement, and Criminal Investigations > Enforcement Actions > Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Apotex Inc. 3/29/10 Warning
More informationWARNING LETTER AUG 3, 2016
Ropack, Inc. 8/3/16 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire Avenue White Oak Building 66 Silver Spring, MD 20993 WARNING LETTER AUG
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationEffective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (COM) COURSE DESCRIPTION
Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (COM) COURSE DESCRIPTION The globalization of the pharmaceutical supply chain has led increased use of Contract Manufacturing
More informationDivi's Laboratories Ltd. (Unit II) 4/13/17
Divi's Laboratories Ltd. (Unit II) 4/13/17 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320 17 34 April 13, 2017 Mr. Kiran S. Divi Director and President of Operations Divi
More informationDivi's Laboratories Ltd. (Unit II) 4/13/17
Divi's Laboratories Ltd. (Unit II) 4/13/17 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320 17 34 April 13, 2017 Mr. Kiran S. Divi Director and President of Operations Divi
More informationQuality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
More informationRegulatory Perspective on Assuring Ingredient Quality
Regulatory Perspective on Assuring Ingredient Quality PQRI Conference December 15, 2009 Rockville, MD Steven M. Wolfgang, Ph.D., Acting Associate Director, Regulatory Science US Food and Drug Administration
More informationOvercome the Top Challenges of Handling OOS Results by Knowing FDA Observations
Overcome the Top Challenges of Handling OOS Results by Knowing FDA Observations Jerry Lanese Ph.D. The Lanese Group, Inc. 2015 The Lanese Group, Inc. 1 Who decided you should come to this conference? On
More informationQuality in Global Sourcing
Quality in Global Sourcing Steve Greer Global Compliance Leader P&G Beauty & Grooming Current Challenges 1 Supplier Related Incidents High profile material contamination incidents have highlighted risks
More informationIntroduction to Medicines Inspections Technical Updates:
Introduction to Medicines Inspections Technical Updates: GMP inspections of Active Pharmaceutical Ingrédients and Finished Pharmaceutical Products (including Reproductive Health Products) Vimal Sachdeva,
More informationMEASURE FOR MEASURE: QUALITY METRICS
MEASURE FOR MEASURE: QUALITY METRICS PDA Midwest Chapter Dinner Meeting, Northbrook, IL-9 November 2017 Felicia Ford-Rice, Director, Strategic Compliance 2017 PAREXEL INTERNATIONAL CORP. AGENDA Robust
More informationJournal home page: RESEARCH ARTICLE
Journal home page: http://www.journalijiar.com INTERNATIONAL JOURNAL OF INNOVATIVE AND APPLIED RESEARCH RESEARCH ARTICLE QUALITY AUDIT AND GMP INSPECTION OF PHARMACEUTICAL INDUSTRY WITH REFERENCE TO USFDA;
More informationComplaints Investigations Root Cause Analysis
Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does
More information22 January Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm Rockville, MD 20852
22 January 2009 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, rm. 1061 Rockville, MD 20852 SUBMISSION OF COMMENTS, DOCKET NO. FDA-2008-D-0559 Dear Sir or Madam:
More informationAllergy Laboratories, Inc. 10/4/13
Allergy Laboratories, Inc. 10/4/13 SEP 04, 2013 Department of Health and Human Services Public Health Service Food and Drug Administration Office of Regulatory Affairs 12420 Parklawn Drive ELEM-2152 Rockville,
More informationContinental Manufacturing Chemist, Inc. 12/21/17
Continental Manufacturing Chemist, Inc. 12/21/17 Division of Pharmaceutical Quality Operations III 300 River Place, Suite 5900 Detroit, MI 48207 Telephone: (313) 393-8100 Fax: (313) 393-8139 December 21,
More informationThe APIC Audit Programme Version 5, July 2017
The APIC Audit Programme Version 5, July 2017 Table of contents 1 General 2. APIC Audit Programme 3 The Auditors 3.1 Educational Background and Experience 3.2 Auditor Training Courses for Certification
More informationEmcure Pharmaceuticals Limited 3/3/16
1 of 7 05/06/2016 8:22 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Emcure Pharmaceuticals Limited 3/3/16 Department of Health and Human Services Public Health Service Food
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationWilson-Hurd ATF Quality Manual
Wilson-Hurd ATF Quality Manual Wilson-Hurd Manufacturing Company Advanced Technical Facility (ATF) 311 Winton Street Wausau, WI 54403 Rev. Date: 04 May 2017 Pete Dehne Vice President, Operations Table
More informationEffective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs)
Effective Quality Oversight of Pharmaceutical Contract Manufacturing Organizations (CMOs) *** LIMITED TIME OFFER: FREE $100 AMAZON GIFT CARD! *** REGISTER TODAY! The globalization of the pharmaceutical
More informationBBT Biotech Gmbh 5/16/16
U.S. Food and Drug Administration Search FDA Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2016 BBT Biotech Gmbh 5/16/16 SHARE
More informationWhy Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services
Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and
More informationResponding to an FDA 483
Responding to an FDA 483 Jim Melancon VP, Associate General Counsel BioScrip, Inc. Marc Stranz, PharmD Healthcare Consultant Disclosure The speakers declare no conflicts of interest or financial interest
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 6 Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Aarti Drugs Limited
More informationApril 12, 2010 WARNING LETTER (10-ATL-12)
Hospira, Inc. Department of Health and Human Services Public Health Service Food and Drug Administration Atlanta District Office 60 8th Street, N.E. Atlanta, Georgia 30309 April 12, 2010 VIA FEDERAL EXPRESS
More informationQuality Management System MANUAL. SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702
Quality Management System MANUAL SDIX, LLC Headquarters: 111 Pencader Drive Newark, Delaware 19702 Doc. No. G5500 Rev. 11 Status : APPROVED Effective: 09/07/2017 Page 2 of 32 Quality Manual Table of Contents
More informationMINIMUM REQUIREMENTS FOR A VENDOR
MINIMUM REQUIREMENTS FOR A VENDOR When outsourcing the production of sterile products the first step in vendor evaluation is to see if they meet the minimum requirements. We ve developed a group of questions
More informationHow Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S)
How Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S) ASQ Northeast Pharmaceutical GMP/Quality Conference January
More information